HRP20231399T1 - Fcrn antitijela i načini njihove uporabe - Google Patents
Fcrn antitijela i načini njihove uporabe Download PDFInfo
- Publication number
- HRP20231399T1 HRP20231399T1 HRP20231399TT HRP20231399T HRP20231399T1 HR P20231399 T1 HRP20231399 T1 HR P20231399T1 HR P20231399T T HRP20231399T T HR P20231399TT HR P20231399 T HRP20231399 T HR P20231399T HR P20231399 T1 HRP20231399 T1 HR P20231399T1
- Authority
- HR
- Croatia
- Prior art keywords
- isolated antibody
- syndrome
- disease
- host cell
- autoimmune
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110071P | 2015-01-30 | 2015-01-30 | |
| US201562258082P | 2015-11-20 | 2015-11-20 | |
| PCT/US2016/015720 WO2016123521A2 (en) | 2015-01-30 | 2016-01-29 | Fcrn antibodies and methods of use thereof |
| EP16744204.5A EP3250610B1 (en) | 2015-01-30 | 2016-01-29 | Fcrn antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231399T1 true HRP20231399T1 (hr) | 2024-02-16 |
Family
ID=56544538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231399TT HRP20231399T1 (hr) | 2015-01-30 | 2016-01-29 | Fcrn antitijela i načini njihove uporabe |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10676526B2 (OSRAM) |
| EP (2) | EP4286011A3 (OSRAM) |
| JP (2) | JP6853178B2 (OSRAM) |
| KR (3) | KR102792441B1 (OSRAM) |
| CN (13) | CN118638229A (OSRAM) |
| AU (2) | AU2016211280B2 (OSRAM) |
| DK (1) | DK3250610T3 (OSRAM) |
| ES (1) | ES2962824T3 (OSRAM) |
| FI (1) | FI3250610T3 (OSRAM) |
| HR (1) | HRP20231399T1 (OSRAM) |
| HU (1) | HUE063778T2 (OSRAM) |
| IL (1) | IL252837B (OSRAM) |
| LT (1) | LT3250610T (OSRAM) |
| NZ (1) | NZ772383A (OSRAM) |
| PL (1) | PL3250610T3 (OSRAM) |
| PT (1) | PT3250610T (OSRAM) |
| RS (1) | RS64768B1 (OSRAM) |
| SG (2) | SG10202007232WA (OSRAM) |
| SI (1) | SI3250610T1 (OSRAM) |
| SM (1) | SMT202300365T1 (OSRAM) |
| WO (1) | WO2016123521A2 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3087095T (lt) | 2013-12-24 | 2019-09-10 | Argenx Bvba | Fcrn-antagonistai ir naudojimo būdai |
| MX2016014355A (es) * | 2014-06-12 | 2017-01-27 | Hoffmann La Roche | Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado. |
| CN118638229A (zh) | 2015-01-30 | 2024-09-13 | 动量制药公司 | Fcrn抗体及其使用方法 |
| WO2018023136A1 (en) * | 2016-07-29 | 2018-02-01 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| CN110785186A (zh) * | 2017-06-15 | 2020-02-11 | Ucb生物制药有限责任公司 | 用于治疗免疫性血小板减少的方法 |
| JP7422659B2 (ja) | 2017-12-08 | 2024-01-26 | アルジェニクス ビーブイ | 全身型重症筋無力症治療のためのＦｃＲｎアンタゴニストの使用 |
| JP7420720B2 (ja) * | 2017-12-13 | 2024-01-23 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| MX2020013195A (es) | 2018-06-08 | 2021-02-26 | Argenx Bvba | Composiciones y metodos para el tratamiento de la trombocitopenia inmunitaria. |
| MX2021000790A (es) * | 2018-07-20 | 2021-07-21 | Momenta Pharmaceuticals Inc | Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas. |
| IL280278B2 (en) * | 2018-07-20 | 2025-10-01 | Momenta Pharmaceuticals Inc | Fcrn antibody preparations |
| EP3866933A1 (en) | 2018-10-16 | 2021-08-25 | UCB Biopharma SRL | Method for the treatment of myasthenia gravis |
| EP3980063A1 (en) | 2019-06-07 | 2022-04-13 | Argenx BVBA | Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration |
| CA3148826A1 (en) * | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
| TW202132346A (zh) * | 2019-11-19 | 2021-09-01 | 瑞士商依牧諾萬科學有限公司 | 使用抗-fcrn抗體治療溫抗體型自體免疫性溶血性貧血之方法 |
| FI4087875T3 (fi) | 2020-01-08 | 2024-10-25 | argenx BV | Vastasyntyneen ihmisen Fc-reseptorin (FcRn) antagonisteja pemfigus-häiriöiden hoitoon |
| EP4240417A4 (en) * | 2020-11-06 | 2024-10-02 | Momenta Pharmaceuticals, Inc. | ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF |
| EP4287828A4 (en) * | 2021-02-02 | 2025-01-15 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric fcrn |
| EP4384548A4 (en) * | 2021-08-13 | 2024-11-13 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | ANTIBODIES SPECIFICALLY RECOGNIZING FCRN AND THEIR USES |
| CN116234827A (zh) * | 2021-09-03 | 2023-06-06 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| KR20250018382A (ko) | 2022-05-30 | 2025-02-05 | 한올바이오파마주식회사 | 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편 |
| WO2023242372A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | Fcrn/hsa binding molecules and methods of use |
| WO2024163894A1 (en) | 2023-02-04 | 2024-08-08 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating hemolytic disease of the fetus and newborn |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025099576A1 (en) | 2023-11-06 | 2025-05-15 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating rheumatoid arthritis |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04007924A (es) | 2002-02-14 | 2005-05-17 | Chugai Pharmaceutical Co Ltd | Formulaciones en solucion que contienen anticuerpo. |
| EP1660128A4 (en) * | 2003-08-08 | 2009-01-21 | Univ New York State Res Found | ANTI-CORR ANTI-BODIES FOR THE TREATMENT OF AUTO / ALLO-IMMUNE DISORDERS |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| KR100996801B1 (ko) | 2005-03-08 | 2010-11-25 | 파마시아 앤드 업존 캄파니 엘엘씨 | 항-ＭＡｄＣＡＭ 항체 조성물 |
| WO2007087289A2 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| CN101421297A (zh) * | 2006-02-17 | 2009-04-29 | 森托尼克斯制药有限公司 | 阻断lgG对FcRn的结合的肽 |
| JP2009529339A (ja) * | 2006-03-13 | 2009-08-20 | アブリンクス エン．ヴェー． | Ｉｌ−６を標的とするアミノ酸配列およびそれを含みｉｌ−６介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド |
| BRPI0910622A2 (pt) * | 2008-04-25 | 2020-03-10 | Dyax Corp. | ANTICORPOS CONTRA FcRn E USOS DOS MESMOS |
| CA2766065C (en) | 2009-06-30 | 2020-07-21 | Research Development Foundation | Immunoglobulin fc polypeptides |
| ES2748583T3 (es) * | 2011-06-02 | 2020-03-17 | Dyax Corp | Proteínas de unión al receptor Fc |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| EP2934587A4 (en) | 2012-12-18 | 2016-08-03 | Merck Sharp & Dohme | Liquid formulations for an anti-TNF-alpha-antibody |
| ES2802274T3 (es) | 2013-05-02 | 2021-01-18 | Momenta Pharmaceuticals Inc | Glicoproteínas sialiladas |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| CN118638229A (zh) | 2015-01-30 | 2024-09-13 | 动量制药公司 | Fcrn抗体及其使用方法 |
| IL295425A (en) * | 2015-03-09 | 2022-10-01 | argenx BV | Methods of reducing serum levels of fc-containing agents using fcrn antagonsits |
| ES2956662T3 (es) | 2015-05-12 | 2023-12-26 | Syntimmune Inc | Anticuerpos anti-FcRn humanizados con afinidad madurada |
| WO2018023136A1 (en) * | 2016-07-29 | 2018-02-01 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| JP7422659B2 (ja) | 2017-12-08 | 2024-01-26 | アルジェニクス ビーブイ | 全身型重症筋無力症治療のためのＦｃＲｎアンタゴニストの使用 |
| JP7420720B2 (ja) | 2017-12-13 | 2024-01-23 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| IL280278B2 (en) | 2018-07-20 | 2025-10-01 | Momenta Pharmaceuticals Inc | Fcrn antibody preparations |
| MX2021000790A (es) | 2018-07-20 | 2021-07-21 | Momenta Pharmaceuticals Inc | Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas. |
-
2016
- 2016-01-29 CN CN202410661131.8A patent/CN118638229A/zh active Pending
- 2016-01-29 PT PT167442045T patent/PT3250610T/pt unknown
- 2016-01-29 CN CN202410661136.0A patent/CN118638230A/zh active Pending
- 2016-01-29 HR HRP20231399TT patent/HRP20231399T1/hr unknown
- 2016-01-29 JP JP2017539428A patent/JP6853178B2/ja active Active
- 2016-01-29 CN CN202410661144.5A patent/CN118562003A/zh active Pending
- 2016-01-29 CN CN202410661152.XA patent/CN118667015A/zh active Pending
- 2016-01-29 CN CN202410661147.9A patent/CN118667012A/zh active Pending
- 2016-01-29 KR KR1020227045647A patent/KR102792441B1/ko active Active
- 2016-01-29 CN CN202410661138.XA patent/CN118652337A/zh active Pending
- 2016-01-29 NZ NZ772383A patent/NZ772383A/en unknown
- 2016-01-29 CN CN202410661133.7A patent/CN118667009A/zh active Pending
- 2016-01-29 EP EP23189767.9A patent/EP4286011A3/en active Pending
- 2016-01-29 WO PCT/US2016/015720 patent/WO2016123521A2/en not_active Ceased
- 2016-01-29 SG SG10202007232WA patent/SG10202007232WA/en unknown
- 2016-01-29 CN CN202410661140.7A patent/CN118667010A/zh active Pending
- 2016-01-29 HU HUE16744204A patent/HUE063778T2/hu unknown
- 2016-01-29 KR KR1020257010788A patent/KR20250052465A/ko active Pending
- 2016-01-29 CN CN202410661149.8A patent/CN118667013A/zh active Pending
- 2016-01-29 LT LTEPPCT/US2016/015720T patent/LT3250610T/lt unknown
- 2016-01-29 SI SI201631739T patent/SI3250610T1/sl unknown
- 2016-01-29 EP EP16744204.5A patent/EP3250610B1/en active Active
- 2016-01-29 CN CN202410661142.6A patent/CN118667011A/zh active Pending
- 2016-01-29 RS RS20231028A patent/RS64768B1/sr unknown
- 2016-01-29 KR KR1020177024165A patent/KR102483016B1/ko active Active
- 2016-01-29 DK DK16744204.5T patent/DK3250610T3/da active
- 2016-01-29 ES ES16744204T patent/ES2962824T3/es active Active
- 2016-01-29 CN CN202110605791.0A patent/CN113384693B/zh active Active
- 2016-01-29 FI FIEP16744204.5T patent/FI3250610T3/fi active
- 2016-01-29 PL PL16744204.5T patent/PL3250610T3/pl unknown
- 2016-01-29 CN CN202410661150.0A patent/CN118667014A/zh active Pending
- 2016-01-29 SM SM20230365T patent/SMT202300365T1/it unknown
- 2016-01-29 SG SG11201705475QA patent/SG11201705475QA/en unknown
- 2016-01-29 CN CN201680008485.6A patent/CN107567460B/zh active Active
- 2016-01-29 US US15/546,870 patent/US10676526B2/en active Active
- 2016-01-29 AU AU2016211280A patent/AU2016211280B2/en active Active
-
2017
- 2017-06-11 IL IL252837A patent/IL252837B/en unknown
-
2020
- 2020-03-20 US US16/825,066 patent/US11732047B2/en active Active
-
2021
- 2021-01-12 JP JP2021002601A patent/JP7224382B2/ja active Active
-
2022
- 2022-02-21 AU AU2022201145A patent/AU2022201145B2/en active Active
-
2023
- 2023-07-13 US US18/351,827 patent/US20240158508A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231399T1 (hr) | Fcrn antitijela i načini njihove uporabe | |
| HRP20161141T1 (hr) | Anti-il-23 protutijela | |
| JP2016527187A5 (OSRAM) | ||
| HRP20240048T1 (hr) | Fcrn antitijela i postupci njihove uporabe | |
| JP2013503204A5 (OSRAM) | ||
| JP2017501725A5 (OSRAM) | ||
| JP7457704B2 (ja) | Ｆｃｒｎ抗体の組成物およびその使用の方法 | |
| SI2889310T1 (en) | Antibody formulations | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20201259T1 (hr) | Protutijela protiv ox40 i njihova upotreba | |
| HRP20200189T1 (hr) | Anti-tigit antitijela, anti-pvrig antitijela i njihove kombinacije | |
| JP2017163973A5 (OSRAM) | ||
| FI3353210T3 (fi) | Tigit-vasta-aineita ja käyttömenetelmiä | |
| JP7599419B2 (ja) | Ｆｃｒｎ抗体組成物 | |
| HRP20170815T1 (hr) | Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe | |
| RU2018113505A (ru) | Il-8-связывающие антитела и их применения | |
| JP2017535261A5 (OSRAM) | ||
| JP2017510575A5 (OSRAM) | ||
| JP2019519527A5 (OSRAM) | ||
| AR110321A1 (es) | Anticuerpos antitau y métodos de uso | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| JP2018509413A5 (OSRAM) | ||
| JP2021506786A5 (OSRAM) | ||
| HRP20190752T1 (hr) | Novo protutijelo protiv ljudskog receptora tslp | |
| JP2016540195A5 (OSRAM) |